We demonstrated that these predicted PD-associated genes were significantly enriched in various PD-related pathobiological pathways: (1) enriched in parkin-dependent substrates and alpha-synuclein (α-syn) modifiers, (2) highly expressed in human brain substantia nigra (SN) region; (3) more likely differentially expressed in human PD brains in cell type-specific manners, including DA neurons; and (4) significantly enriched in literature-reported PD pathways and known drug targets. The gene discussed is PRKN; the disease is Parkinson disease.